Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome
2
조회
0
다운로드
12
인용
0
참고문헌
키워드
초록
Background/Aims: Irritable bowel syndrome (IBS) is a troublesome disease. Some strains of probiotics reportedly exert remarkable immunomodulatory effects, and so we designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with IBS. Methods: IBS patients who met Rome III criteria were randomly assigned to receive composite probiotics or placebo. A total of 20 billion lyophilized bacteria were administered twice daily for 8 weeks. Primary outcome variables were symptom scores consisting of abdominal pain, flatulence, defecation discomfort, and sum of symptom scores. A visual analogue scale was used to quantify the severity. Secondary outcome variables consisted of the quality of life and bowel habits including defecation frequency and stool form. Results: Thirty-six and 34 patients were randomized to the probiotics and placebo groups, respectively. Intentionto- treat analysis showed significant reductions in pain after 8 weeks of treatment: −31.9 and −17.7 in the probiotics and placebo groups, respectively (p=0.045). The reductions in abdominal pain, defecation discomfort, and sum of scores were more significant in 58 patients with a score of at least 3 on the baseline stool-form scale. Conclusions: Composite probiotics containing Bifidobacterium bifidum BGN4, Lactobacillus acidophilus AD031, and other species are safe and effective, especially in patients who excrete normal or loose stools.
Abstract
Background/Aims: Irritable bowel syndrome (IBS) is a troublesome disease. Some strains of probiotics reportedly exert remarkable immunomodulatory effects, and so we designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with IBS. Methods: IBS patients who met Rome III criteria were randomly assigned to receive composite probiotics or placebo. A total of 20 billion lyophilized bacteria were administered twice daily for 8 weeks. Primary outcome variables were symptom scores consisting of abdominal pain, flatulence, defecation discomfort, and sum of symptom scores. A visual analogue scale was used to quantify the severity. Secondary outcome variables consisted of the quality of life and bowel habits including defecation frequency and stool form. Results: Thirty-six and 34 patients were randomized to the probiotics and placebo groups, respectively. Intentionto- treat analysis showed significant reductions in pain after 8 weeks of treatment: −31.9 and −17.7 in the probiotics and placebo groups, respectively (p=0.045). The reductions in abdominal pain, defecation discomfort, and sum of scores were more significant in 58 patients with a score of at least 3 on the baseline stool-form scale. Conclusions: Composite probiotics containing Bifidobacterium bifidum BGN4, Lactobacillus acidophilus AD031, and other species are safe and effective, especially in patients who excrete normal or loose stools.
참고문헌 (22)
- Everhart JE, "Irritable bowel syndrome in office- based practice in the United States", Gastroenterology, 100, pp.998~1005 (1991)
- Talley NJ, "Epidemiology of colonic symptoms and the irritable bowel syndrome", Gastroenterology, 101, pp.927~934 (1991)
- Park KS, "A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients", Dig Dis Sci, 53, pp.704~711 (2008)
- Chadwick VS, "Activation of the mucosal immune system in irritable bowel syndrome", Gastroenterology, 122, pp.1778~1783 (2002)
- Liebregts T, "Immune activation in patients with irritable bowel syndrome", Gastroenterology, 132, pp.913~920 (2007)
- Kim HJ, "A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome", Aliment Pharmacol Ther, 17, pp.895~904 (2003)
- Kim HJ, "A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating", Neurogastroenterol Motil, 17, pp.687~696 (2005)
- Whorwell PJ, "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome", Am J Gastroenterol, 101, pp.1581~1590 (2006)
- Riedel CU, "Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation", World J Gastroenterol, 12, pp.3729~3735 (2006)
- PARK, MYEONG SOO, "Assessment of Lipopolysaccharide-binding Activity of Bifidobacterium andIts Relationship with Cell Surface Hydrophobicity, Autoaggregation, andInhibition of Interleukin-8 Production", Journal of Microbiology and Biotechnology, 17(7), pp.1120~1126 (2007), 한국미생물·생명공학회
- Kim N, "Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation", Clin Immunol, 123, pp.30~39 (2007)
- Heaton KW, "Defecation frequency and timing, and stool form in the general population: a prospective study", Gut, 33, pp.818~824 (1992)
- Heaton KW, "How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome?. in: A prospective, controlled study with emphasis on stool form", Gut, 32, pp.73~79 (1991)
- Hays RD, "The RAND 36-Item Health Survey 1.0", Health Econ, 2, pp.217~227 (1993)
- Patel SM, "The placebo effect in irritable bowel syndrome trials: a meta-analysis", Neurogastroenterol Motil, 17, pp.332~340 (2005)
- Williams EA, "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study", Aliment Pharmacol Ther, 29, pp.97~103 (2009)
- Dorn SD, "A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome", Neurogastroenterol Motil, 19, pp.630~637 (2007)
- Musial F, "Placebo responses in patients with gastrointestinal disorders", World J Gastroenterol, 13, pp.3425~3429 (2007)
- Camilleri M, "Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy", J Clin Gastroenterol, 40, pp.264~269 (2006)
- Kassinen A, "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects", Gastroenterology, 133, pp.24~33 (2007)
- Rousseaux C, "Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors", Nat Med, 13, pp.35~37 (2007)
- Sinn DH, "Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome", Dig Dis Sci, 53, pp.2714~2718 (2008)